Instrument Inactif

Autres langues Access Pharmaceuticals, Inc. OTC Bulletin Board

Actions

ACCP

US00431M3088

Produits pharmaceutiques

Cours en clôture OTC Bulletin Board
- ^USD	-

16/09	Transcript : Abeona Therapeutics Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 11:30 AM
16/09	Abeona Therapeutics active l'University of Florida Health comme centre de traitement qualifié pour le Zevaskyn	CI

Autres langues

18/09	Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
16/09	Abeona Therapeutics Activates University of Florida Health as Qualified Treatment Center for Zevaskyn
16/09	Abeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida
16/09	Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
02/09	Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
01/09	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/08	Abeona Therapeutics Shares Fall After Q2 Miss
13/08	Abeona Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Abeona Therapeutics: Q2 Earnings Snapshot
13/08	Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
06/08	Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
04/08	Abeona Therapeutics Inc. Grants New Technology Add-On Payment Status For ZEVASKYN
04/08	Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08	CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
03/08	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21/07	Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
01/07	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Growth Benchmark
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) added to Russell 2000 Value-Defensive Index
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000 Growth Benchmark
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) added to Russell 2000 Defensive Index
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell Microcap Growth Benchmark Index
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell Small Cap Comp Growth Benchmark
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 2500 Growth Benchmark
29/06	Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 2000 Growth Benchmark